For the patient who presents with a new diagnosis of SLE, or for the one who has a flare in previously established disease, the immediate need is to achieve control of the inflammatory process.

Drug-induced lupus is more common in men because they are given these drugs more often; however, not everyone who takes these drugs will develop the disease. Specific criteria for diagnosing ...

Medicare covers lupus treatment in different ways depending on your age and how the condition affects you. Read more.

Charles River Laboratories International, Inc. CRL and Valo Health, Inc. recently announced an advanced product candidate for the treatment of different forms of lupus and other autoimmune indications ...

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Merck’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development of the drug is set to continue. Announced in the company’s Q4 ...

Belimumab, a monoclonal antibody that targets B lymphocyte stimulator (BLYS; also known as TNFSF13B and BAFF), developed by Human Genome Sciences and GlaxoSmithKline, met the primary end point in ...

Looking for reliable medications to treat 'Systemic Lupus Erythematosus'? This page offers a detailed resource for the most up-to-date treatment options, including both generic and brand-name ...

Systemic lupus erythematosus (SLE) is a complex, chronic, autoimmune disorder that involves multiple organ systems including the skin, joints, heart, lungs, blood, kidneys and, in the most severe ...